Clinical Trial Detail

NCT ID NCT03375307
Title Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

bladder urothelial carcinoma

transitional cell carcinoma

Therapies

Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST